<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03656445</url>
  </required_header>
  <id_info>
    <org_study_id>546a - 26/10/2015</org_study_id>
    <nct_id>NCT03656445</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid in Total Knee Replacement</brief_title>
  <official_title>Multiple Intravenous Tranexamic Acid Doses Can Reduce Postoperative Blood Loss and Improve the Functional Outcome in Total Knee Arthroplasty Without Tourniquet: a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Democritus University of Thrace</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Democritus University of Thrace</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple intravenous Tranexamic Acid doses can reduce postoperative blood loss and improve
      the functional outcome in total knee arthroplasty without tourniquet: a randomized controlled
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 180 patients undergoing TKA for knee osteoarthritis were stratified in three equal
      groups. All surgeries were performed under spinal anesthesia, without tourniquet and patients
      should be in agreement with the established inclusion/exclusion criteria. Group A (60
      patients) received 1g of IV TXA, Group B (60 patients) received an additional dose of IV TXA
      and Group C (60 patients) received three doses of IV TXA. The measured outcomes were the
      Hemoglobin (Hb) decrease, the transfusion rate, the functional, quality of life (QoL) and
      pain assessment based on their corresponding scoring system.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2015</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">March 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hemoglobin change</measure>
    <time_frame>1st,2nd and 4th post-operative day</time_frame>
    <description>Hemoglobin decrease/change during the four post-operative days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood loss</measure>
    <time_frame>24 hours</time_frame>
    <description>calculated total blood loss (TBL) the 1st post-op day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood loss</measure>
    <time_frame>48 hours</time_frame>
    <description>calculated total blood loss (TBL) the 2nd post-op day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood loss</measure>
    <time_frame>96 hours</time_frame>
    <description>calculated total blood loss (TBL) the 4th post-op day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet count change</measure>
    <time_frame>24 hours, 48 hours, 96 hours</time_frame>
    <description>Platelet count increase/decrease/change during the 1st,2nd and 4th day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Need for trasfussion</measure>
    <time_frame>24 hours</time_frame>
    <description>Transfussion rate/quantity in 1st post-op day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Need for trasfussion</measure>
    <time_frame>48 hours</time_frame>
    <description>Transfussion rate/quantity in 2nd post-op day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Need for trasfussion</measure>
    <time_frame>96 hours</time_frame>
    <description>Transfussion rate/quantity in 3rd post-op day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee Society Score (KSS) KSS</measure>
    <time_frame>2nd and 4th post op days + 6th week and 12th week</time_frame>
    <description>Change in this Score which is an objective scoring system to rate the knee and patient's functional abilities such as walking and stair climbing before and after TKA. Maximum score is 100 (best functionality) and lowest score is 0 (worst functionality)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function Knee Society Score</measure>
    <time_frame>2nd and 4th post op days + 6th week and 12th week</time_frame>
    <description>Change in this score which utilizes walking distance and stair climbing as the main parameters, with deduction for the use of a walking aid. Maximum score is 100 (best functionality) and lowest score is 0 (worst functionality)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol</measure>
    <time_frame>2nd and 4th post op days + 6th week and 12th week</time_frame>
    <description>Changes in this score which is a standardised measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. Crosswalk value sets for the EQ-5D-5L has been used to asses the results into numbers. Maximum score is 1 (which means best quality of life) and the lowest is -0.594(which means the worst quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS pain (analogue pain scale)</measure>
    <time_frame>2nd and 4th post op days + 6th week and 12th week</time_frame>
    <description>The pain VAS is a continuous scale comprised of a horizontal (HVAS) or vertical (VVAS) line, usually 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme. For pain intensity, the scale is most commonly anchored by &quot;no pain&quot; (score of 0) and &quot;pain as bad as it could be&quot; or &quot;worst imaginable pain&quot; (score of 10 [100‚Äêmm scale])</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Osteo Arthritis Knee</condition>
  <arm_group>
    <arm_group_label>Group A - Tranexamic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - Tranexamic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C - Tranexamic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia</description>
    <arm_group_label>Group A - Tranexamic Acid</arm_group_label>
    <other_name>Transamin</other_name>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision</description>
    <arm_group_label>Group B - Tranexamic Acid</arm_group_label>
    <other_name>Transamin</other_name>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectivel</description>
    <arm_group_label>Group C - Tranexamic Acid</arm_group_label>
    <other_name>Transamin</other_name>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. varus deformity less than 10o

          2. lack of extension not more than 10o

          3. flexion of at least 90o.

        Exclusion Criteria:

          1. uncontrolled medical diseases/comorbidities

          2. allergy and/or hypersensitivity to TXA

          3. a known history of thromboembolic disease, cardiovascular disease

          4. coronary or vascular stent placed within the past 12 months

          5. cerebral vascular disease (a history of stroke)

          6. subarachnoid hemorrhage

          7. preoperative coagulopathy (a platelet [PLT] count &lt;150,000/mm3 or an international
             normalized ratio greater than 1.5

          8. preoperative renal or hepatic dysfunction

          9. retinal vein or artery occlusion

         10. patients with anemia (&lt;12 g/dL for female, &lt;13 g/dL for male)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clinics in geriatric medicine. Aug 2010;26(3):355-369. 2. Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis. British medical bulletin. 2013;105:185-199. 3. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. The Journal of bone and joint surgery. American volume. Apr 2007;89(4):780-785. 4. Bourne RB, McCalden RW, MacDonald SJ, Mokete L, Guerin J. Influence of patient factors on TKA outcomes at 5 to 11 years followup. Clinical orthopaedics and related research. Nov 2007;464:27-31. 5. Anderson JG, Wixson RL, Tsai D, Stulberg SD, Chang RW. Functional outcome and patient satisfaction in total knee patients over the age of 75. The Journal of arthroplasty. Oct 1996;11(7):831-840. 6. Mulhall KJ, Ghomrawi HM, Bershadsky B, Saleh KJ. Functional improvement after total knee arthroplasty revision: new observations on the dimensional nature of outcome. Journal of orthopaedic surgery and research. Dec 07 2007;2:25. 7. Saleh KJ, Dykes DC, Tweedie RL, et al. Functional outcome after total knee arthroplasty revision: a meta-analysis. The Journal of arthroplasty. Dec 2002;17(8):967-977. 8. Sikorski JM. Alignment in total knee replacement. The Journal of bone and joint surgery. British volume. Sep 2008;90(9):1121-1127. 9. Blumberg N. Allogeneic transfusion and infection: economic and clinical implications. Semin Hematol. 1997/07// 1997;34(3 Suppl 2):34-40. 10. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. Apr 09 2009;113(15):3406-3417. 11. Berry DJ, Bozic KJ. Current practice patterns in primary hip and knee arthroplasty among members of the American Association of Hip and Knee Surgeons. The Journal of arthroplasty. Sep 2010;25(6 Suppl):2-4. 12. Themistoklis T, Theodosia V, Konstantinos K, Georgios DI. Perioperative blood management strategies for patients undergoing total knee replacement: Where do we stand now? World journal of orthopedics. Jun 18 2017;8(6):441-454. 13. Zhang W, Li N, Chen S, Tan Y, Al-Aidaros M, Chen L. The effects of a tourniquet used in total knee arthroplasty: a meta-analysis. Journal of orthopaedic surgery and research. 2014;9:13-13. 14. Zhang Q, Dong J, Gong K, Li X, Zheng S, Wen T. [Effects of Tourniquet Use on Perioperative Outcome in Total Knee Arthroplasty]. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery. Apr 2016;30(4):421-425. 15. Du Z, Liu P, Zhang Y, Li D, Li M. [Effect of tourniquet on perioperative blood loss and short-term effectiveness in total knee arthroplasty]. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery. Nov 2013;27(11):1318-1323. 16. Li X, Yin L, Chen ZY, et al. The effect of tourniquet use in total knee arthroplasty: grading the evidence through an updated meta-analysis of randomized, controlled trials. European journal of orthopaedic surgery &amp; traumatology : orthopedie traumatologie. Aug 2014;24(6):973-986. 17. Tetro AM, Rudan JF. The effects of a pneumatic tourniquet on blood loss in total knee arthroplasty. Canadian journal of surgery. Journal canadien de chirurgie. Feb 2001;44(1):33-38.</citation>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>August 31, 2018</last_update_submitted>
  <last_update_submitted_qc>August 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Democritus University of Thrace</investigator_affiliation>
    <investigator_full_name>Tzatzairis Themistoklis</investigator_full_name>
    <investigator_title>Principal investigator Dr. Tzatzairis Themistoklis</investigator_title>
  </responsible_party>
  <keyword>total knee arthroplasty</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>without tourniquet</keyword>
  <keyword>blood loss</keyword>
  <keyword>function</keyword>
  <keyword>multiple doses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

